Anemia Epidemiology Forecast to 2030 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

The "Anemia - Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This 'Iron deficiency anemia (IDA)- Epidemiology Forecast to 2030' report delivers an in-depth understanding of the IDA across the several selected cancer types, historical and forecasted IDA epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Epidemiology Perspective

The IDA epidemiology division provides the insights about historical and current indication wise eligible patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted IDA epidemiology [segmented as Total prevalent cases of IDA, Total diagnosed prevalent cases of IDA, Total IDA cases by gender, Total IDA cases by pathology, Severity specific diagnosed cases of IDA, and Total Treated cases of IDA] scenario of IDA in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030.

Country Wise- IDA Epidemiology

In 2020, the total prevalent cases of IDA were 30,829,734 in the 7MM. The United States, in the same year, accounted for 9,313,895 cases. According to the analysis, Japan had the highest prevalence of IDA cases in the 7MM, accounting for approximately 39% of the total 7MM cases in 2020.

IDA is often underdiagnosed and undertreated, as some people may not have any symptoms at first. In the EU-5 countries, the total diagnosed prevalent cases of IDA were 4,277,646 in 2020. Many programs have been launched in an attempt to minimize the prevalence of IDA in the Western world. Screening, health education, iron fortification of food, and increased usage of iron-rich baby formula are among them.

Females are more likely to be afflicted by IDA than men. In 2020, the total IDA cases in women health were estimated around 2,060,787 in the 7MM. Among all the pathology related cause of IDA, IDA in chronic kidney disease have the highest patient pool in 2020.

When a patient is diagnosed with IDA, an iron-rich diet and oral iron supplements can help treat the majority of mild-to-moderate IDA cases. In the 7MM, it is accessed that 9,266,923 cases received first-line oral therapies. Some of the patients who have received first-line oral treatments fail and move to second-line oral medications such as Feraccru (Accrufer) and Auryxia (Riona). Moreover, some proportion of patients who receive second-line oral treatments and who have severe IDA will proceed to IV iron therapy.

Reasons to Buy

Story continues

Develop business strategies by understanding the trends shaping and driving the global IDA market

Quantify patient populations in the global IDA market to improve product design, pricing, and launch plans

Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for IDA therapeutics in each of the markets covered

The IDA epidemiology report and model were written and developed by Masters and PhD level epidemiologists

The IDA Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Executive Summary of Iron deficiency Anemia

3.1. Key Events

4. Epidemiology Forecast Flow

5. Background and Overview

5.1. Introduction

5.2. Anemia

5.2.1. Types of Anemia

5.3. Iron deficiency Anemia

5.4. Signs and Symptoms of IDA

5.5. Causes of IDA

5.6. Risk factors of IDA

5.7. Pathophysiology of IDA

5.7.1. Iron Cycle

5.7.2. Stages of Iron Deficiency

5.8. Diagnosis of IDA

5.8.1. Differential Diagnosis

5.8.2. Diagnostic Algorithm of IDA

5.8.3. Academy of Family Physicians (AAFP) Guidelines for the Diagnosis of IDA

5.8.4. British Society of Gastroenterology Guidelines for the Diagnosis of IDA in Gastrointestinal (GI) Diseases

5.8.5. UK National Screening Committee (NSC) Screening Recommendation

6. Treatment

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Assumptions and Rationale

7.3. Epidemiology Scenario (7MM)

7.3.1. Total prevalent cases of Iron Deficiency Anemia (IDA) in the 7MM

7.3.2. Total diagnosed prevalent cases of Iron Deficiency Anemia (IDA) in the 7MM

7.3.3. Total Iron Deficiency Anemia (IDA) cases by gender in the 7MM

7.3.4. Total Iron Deficiency Anemia (IDA) cases by pathology in the 7MM

7.3.5. Severity-Specific Diagnosed cases of IDA in the 7MM

7.3.6. Total treated cases of Iron Deficiency Anemia (IDA) in the 7MM

8. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/v6cbei

View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005908/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900